Evaluating the landscape and characteristics of endometriosis research published between 1990 and 2024

Systematic review / meta-analysis OA: gold CC0
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-29 ⓘ

This study analyzed 536 endometriosis RCTs from 1990-2024, finding a rise in complementary therapy research and a high proportion underpowered to detect clinically significant effects, with the US and China leading publications.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-17 · read from full text ⓘ

This bibliometric analysis evaluated 536 randomized controlled trials on endometriosis published between 1990 and 2024 to assess trends in management types, geographic origins, and statistical power. The study found that medical management dominated the literature, with a significant portion focusing on GnRH analogues despite their status as second-line treatments, while complementary therapies saw a sharp rise in recent years. A major limitation identified was that over half of the trials with continuous outcomes were underpowered at 90% power to detect anything but large effect sizes, suggesting potential resource inefficiency. This paper is centrally about endometriosis — specifically analyzing the landscape, methodology, and power limitations of clinical trials investigating its treatment.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PURPOSE: We aimed to assess the landscape of endometriosis randomised-controlled trials (RCTs) between 1990 and 2024 by characterising RCTs by management type, primary outcome, country of origin, trial registration, sample size and minimum detectable difference based upon standard RCT power targets of 80% and 90%. METHODS: We identified all endometriosis RCTs from Dimensions.AI with an English abstract. Articles were examined for sample size, theme and primary outcome. Sample sizes were used to calculate minimum detectable effect size (MDES) of studies at 80% and 90% power. RESULTS: We analysed 536 RCTs using 'R'. 55.6% (N = 298) of studies investigated medical management of endometriosis, of which 177 investigated Gonadotrophin Releasing Hormone (GnRH) analogues. RCTs investigating complementary therapies rose from 0.847% (N = 1) in 1990-1999 to 28.7% (N = 31) of medical management RCTs in 2020-2024. The US and China led publishing with 70 and 65 RCTs total, respectively. Importantly, of 445 RCTs with at least one continuous outcome, we found that at 90% power, 55.7% (N = 248) of RCTs would only detect a standardised mean difference which was 'large' or greater. CONCLUSION: We noted several trends within endometriosis RCTs. In line with wider literature, China accounts for a growing proportion of RCTs. Although complementary therapy is increasingly recognised as a management option requiring further research, most medical management RCTs focussed on GnRH analogues as part of their treatment regime despite these being considered second-line management options. A high proportion of RCTs was underpowered to detect potentially clinically significant effects of intervention-potentially indicating significant resource wastage.
Full text 3,766 characters · extracted from oa-html · 4 sections · click to expand

Abstract

Purpose We aimed to assess the landscape of endometriosis randomised-controlled trials (RCTs) between 1990 and 2024 by characterising RCTs by management type, primary outcome, country of origin, trial registration, sample size and minimum detectable difference based upon standard RCT power targets of 80% and 90%.

Methods

We identified all endometriosis RCTs from Dimensions.AI with an English abstract. Articles were examined for sample size, theme and primary outcome. Sample sizes were used to calculate minimum detectable effect size (MDES) of studies at 80% and 90% power.

Results

We analysed 536 RCTs using ‘R’. 55.6% (N = 298) of studies investigated medical management of endometriosis, of which 177 investigated Gonadotrophin Releasing Hormone (GnRH) analogues. RCTs investigating complementary therapies rose from 0.847% (N = 1) in 1990–1999 to 28.7% (N = 31) of medical management RCTs in 2020–2024. The US and China led publishing with 70 and 65 RCTs total, respectively. Importantly, of 445 RCTs with at least one continuous outcome, we found that at 90% power, 55.7% (N = 248) of RCTs would only detect a standardised mean difference which was ‘large’ or greater.

Conclusion

We noted several trends within endometriosis RCTs. In line with wider literature, China accounts for a growing proportion of RCTs. Although complementary therapy is increasingly recognised as a management option requiring further research, most medical management RCTs focussed on GnRH analogues as part of their treatment regime despite these being considered second-line management options. A high proportion of RCTs was underpowered to detect potentially clinically significant effects of intervention—potentially indicating significant resource wastage. Similar content being viewed by others Funding Open Access funding enabled and organized by CAUL and its Member Institutions. The authors declare that no funds, grants, or other supports were received during the preparation of this manuscript. Author information Authors and Affiliations Corresponding author Ethics declarations Conflict of interest QF reports scholarships from Merck, Monash University, and China Scholarship Council. BWM reports consultancy, travel support, and research funding from Merck and consultancy for Ferring, Organon, and Norgine. Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary Information Below is the link to the electronic supplementary material. Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. About this article Cite this article Mago, S., Grimes, D.R., Feng, Q. et al. Evaluating the landscape and characteristics of endometriosis research published between 1990 and 2024. Arch Gynecol Obstet (2026). https://doi.org/10.1007/s00404-026-08516-x Received: Accepted: Published: DOI: https://doi.org/10.1007/s00404-026-08516-x

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

SciLite annotations

chemicals 3
mineral danazol gestrinone

Source provenance

europepmc
last seen: 2026-11-21T06:17:04.340742+00:00
openalex
last seen: 2026-10-26T06:07:52.047309+00:00
pubmed
last seen: 2026-11-21T06:09:49.980590+00:00
scilite
last seen: 2026-11-08T10:40:02.467495+00:00
License: CC0 · commercial use OK